Meta-analysis: Travel and Risk for Venous Thromboembolism

Divay Chandra, MD, MSc; Emilio Parisini, MSc, PhD; and Dariush Mozaffarian, MD, DrPH

Background: The potential risk for travel-related venous thromboembolism (VTE) has become an important public health concern because of rapid increases in long-distance travel; however, previous studies on this relationship are surprisingly contradictory.

Purpose: To estimate the risk for VTE in travelers, determine whether a dose–response relationship exists, and identify reasons for the contradictory results of previous studies.

Data Sources: MEDLINE, EMBASE, BIOSIS, CINAHL, grey-literature sources, contact with investigators, and reference lists of studies, without language restrictions.

Study Selection: Reports were selected if they investigated the association between travel and VTE for persons who used any mode of transportation and if nontraveling persons were included for comparison.

Data Extraction: Data on study and patient characteristics, risk estimates, and quality were independently extracted by 2 investigators. Pooled effect estimates were obtained by using random-effect meta-analysis.

Data Synthesis: Of 1560 identified abstracts, 14 studies (11 case–control, 2 cohort, and 1 case–crossover) met inclusion criteria, including 4055 cases of VTE. Compared with nontravelers, the overall pooled relative risk for VTE in travelers was 2.0 (95% CI, 1.5 to 2.7). Significant heterogeneity was present because of the method for selecting control participants (P = 0.008): whether the studies used control participants who had been referred for VTE evaluation or nonreferred control participants. When the studies that used referred control participants were excluded, the pooled relative risk for VTE in travelers was 2.8 (CI, 2.2 to 3.7), without significant heterogeneity. A dose–response relationship was identified, with an 18% higher risk for VTE for each 2-hour increase in duration of travel by any mode (P = 0.010) and a 26% higher risk for every 2 hours of air travel (P = 0.005).

Limitation: All available studies were from Western countries; generalizability to non-Western populations is expected but needs confirmation.

Conclusion: Travel is associated with a nearly 3-fold higher risk for VTE, with a dose–response relationship of 18% higher risk for each 2-hour increase in travel duration. Heterogeneity in results of previous studies was due to selection bias toward the null from use of referred control participants.

Because of the rapid increase in air and other modes of travel in recent years, the potential risk for travel-related venous thromboembolism (VTE) is a growing public health concern (1). Worldwide, 2.5 billion passengers will travel by air in 2010 (2), which underscores the large global population at risk for this serious condition. In addition to the direct and indirect costs of evaluation and treatment, mortality risk is high: In ambulatory population-based cohorts, the estimated 28-day mortality for a first episode of VTE is 11% (3). Although a positive relationship between travel and VTE is often discussed and assumed to exist, the results of previous studies are surprisingly conflicting. Several epidemiologic studies have investigated this relationship over the past decade; approximately half have found no relationship between travel and VTE (4–8), whereas the rest have identified elevated risk (9–16). Demonstrating the presence and magnitude of such potential risk is crucial to determine the appropriateness of additional controlled trials or policy measures to prevent travel-related VTE. In addition, if a relationship exists, quantifying the dose–response relationship—how duration of travel relates to VTE—is central to determining the travel circumstances under which sufficient risk could be present to justify preventive interventions.

To determine whether travel is associated with risk for VTE, to quantify the dose–response relationship, and to identify reasons for the contradictory findings reported by previous studies, we performed a systematic review and meta-analysis of studies of travel and risk for VTE. We hypothesized that travel would be associated with the risk for VTE and that this risk would increase with greater duration of travel.

Methods

We followed the MOOSE (Meta-analysis of Observational Studies in Epidemiology) guidelines during all stages of design, implementation, and reporting of this meta-analysis (17).

Search Strategy and Data Sources

We searched for all studies that provided an effect estimate for a potential association between travel and VTE. Inclusion criteria were observational studies or clinical trials that included patients who traveled by any mode of transportation; that used nontraveling persons for com-
Travel and Risk for Venous Thromboembolism

Study Selection

Of 1560 identified abstracts, we excluded 1518 on screening because they were commentaries, general reviews, or case reports (Figure 1). Two investigators independently examined the full text of the remaining 42 studies to confirm eligibility for inclusion. The second reviewer was blinded to the study investigators and journal of publication. Interobserver agreement between the 2 reviewers for initial study inclusion was high ($k = 0.89$). We resolved disagreement by mutual discussion and, if required, by consultation with a third investigator. Of the 42 studies, we excluded 15 because they lacked a nontraveling comparison group, 11 because they evaluated preventive measures for travel-related VTE, 1 because it did not use the required criteria for VTE diagnosis (18), and 1 because no events occurred and it also lacked a nontraveling comparison group (19). This resulted in the final selection of 14 studies, including 1 prospective cohort study (15), 1 retrospective cohort study (16), 1 case–crossover study (13), and 11 case–control studies (4–12, 14, 20). The investigators can provide a complete list of abstracts searched with reasons for exclusion on request.

Data Extraction and Quality Assessment

We collected data on the year the study was performed, study design, study location, inclusion and exclusion criteria, number of participants, duration and mode of travel, duration of follow up, and adjusted relative risks and odds ratios with CIs. Two investigators performed independent data extraction by using a standardized data collection form. We resolved disagreement by mutual discussion and, if required, by consulting a third investigator. All prespecified data points were available from the pub-

**Figure 1. Study flow diagram.**

- Abstracts selected for review by 1 reviewer ($n = 1560$)
- Abstracts excluded on initial screening: review articles, commentaries, and case reports ($n = 1518$)
- Studies selected for full review by 2 reviewers ($n = 42$)
- Studies excluded on full review ($n = 28$)
  - No nontraveling comparison group: 15
  - Evaluated preventive measures: 11
  - No VTE events and no nontraveling comparison group: 1
  - Lacked required diagnostic criteria for VTE: 1
- Articles reporting results from 14 studies selected ($n = 13$)

VTE = venous thromboembolism.
lished manuscripts, except for data on dose-response (duration of travel and risk for VTE) in 4 studies (11–13, 15); we contacted the investigators to request the missing data but received no responses. Because no standardized criteria have been established for judging the quality of observational studies, quality scores can differ depending on the scale chosen, and interpretation of such scores is difficult (21), we selected a priori several important design characteristics that may affect study quality to evaluate as sources of heterogeneity, including inclusion and exclusion criteria, method of travel history assessment, selection criteria for control participants, matching criteria, and control for confounding. We were particularly interested in the selection criteria for control participants in case–control studies because of the potential for selection bias that could substantially alter the validity of the obtained results. We assessed potential recall bias by the method (self-report vs. travel records) and timing (before vs. after VTE evaluation) of travel history assessment.

### Statistical Analysis

We obtained pooled risk estimates for risk for VTE with travel by using random-effects models, according to the method of DerSimonian and Laird (22), with inverse-variance weighting. We used the most fully multivariable-adjusted effect estimate and recorded the included covariates. Because travel-related VTE is an uncommon outcome, odds ratios from case–control studies approximate risk ratios or relative risks (RRs) from cohort studies, and we pooled them to generate 1 common RR. Henceforth, we will refer to odds ratios from case–control studies as RRs. We assessed heterogeneity among studies by using Cochrane $Q$ and $I^2$ statistics. We evaluated the following predefined sources of potential heterogeneity: study design (cohort vs. case–crossover vs. case–control), selection criteria for control participants in case–control studies (referred for VTE evaluation vs. nonreferred), study location (Europe vs. North America vs. Australia or New Zealand), minimum duration of travel required for inclusion (<8 vs.

| Table 1. Included Studies |
|--------------------------|
| **Study, Year (Reference)** | **Study Location** | **VTE Events, n** | **Case Confirmation** | **Control Group (Non–Case Patients)** | **Minimum Duration of Travel, h** |
| **Cohort studies** | | | | | |
| Schwarz et al, 2003 (15) | Europe | 7 | Radiology | All non–case patients in the cohort | 8 |
| Kuipers et al, 2007 (16) | United States and Europe | 22 | Radiology | All non–case patients in the cohort | 4 |
| **Case–crossover studies** | | | | | |
| Kelman et al, 2003 (13) | Australia | 46 | Hospital admission for VTE | Within-person analysis of non–case-patient time | 0 |
| **Case–control studies with nonreferred control population** | | | | | |
| Ferrari et al, 1999 (11) | Europe | 160 | Radiology | Hospitalized with first episode of chest pain, arterial hypertension, or syncope‡ | 4 |
| Samama, 2000 (12) | Europe | 494 | Radiology | Outpatients with influenza or rhinopharyngeal syndrome matched by age and sex | Not reported |
| Cannegieter et al, 2006 (10) | Europe | 1906 | Radiology | Matched partners of cases | 4 |
| Parkin et al, 2006 (9) | New Zealand | 88 | Autopsy§ | Matched subjects from electoral roll | 3 |
| Martinelli et al, 2003 (14) | Europe | 210 | Radiology | Healthy volunteers | 8 |
| **Case–control studies with referred control population** | | | | | |
| Kraaijenhagen et al, 2000 (4) | Europe | 186 | Radiology| Referred for VTE but tested negative¶ | 3 |
| Arya et al, 2002 (6) | Europe | 185 | Radiology| Referred for VTE but tested negative¶ | 3 |
| Hosoi et al, 2002 (7) | Europe | 101 | Radiology| Referred for VTE but tested negative¶ | 3 |
| ten Wolde et al (study 1), 2003 (5) | Europe | 58 | Radiology| Referred for VTE but tested negative¶ | 3 |
| ten Wolde et al (study 2), 2003 (5) | Europe | 233 | Radiology| Referred for VTE but tested negative¶ | 3 |
| Opatrny, 2004** (8) | Canada | 359 | Radiology| Referred for VTE but tested negative¶ | 0 |

DVT = deep venous thrombosis, PE = pulmonary embolism, VTE = venous thromboembolism.

* Method of ascertainment was the same for all participants in each study.
† Odds ratios for case–control and case–crossover studies and relative risks for cohort studies.
‡ We excluded patients with preexisting mobility restrictions and those who were receiving anticoagulants.
§ Eight cases were confirmed on the basis of pulmonary angiography and ventilation–perfusion scans, and 4 were confirmed by 2 internists who used standard criteria and were blinded to exposure status.
¶ Investigators also used D-dimer testing and clinical probability scores to rule out VTE in control participants.
** Patients were referred for radiologic work-up of suspected VTE, found to have negative test results, and included as control participants.

182 4 August 2009 Annals of Internal Medicine Volume 151 • Number 3 www.annals.org
duration of follow-up after travel completed (≤3 vs. >3 weeks), type of VTE studied (DVT vs. PE), mode of travel (air vs. surface [land or sea]), exposure assessment (self-report vs. travel records), and number of included covariates. We obtained effect estimates by mode of travel from the individual studies or, when such estimates were unavailable, from previously reported pooled estimates (5). We used meta-regression to examine sources of heterogeneity by using the Wald test in random-effects meta-regression models. We also used meta-regression to test for a dose–response relationship between duration of travel and risk for VTE. We assessed potential publication bias by visually examining a funnel plot with the Begg test (23), a statistical analogue of the visual funnel graph, and the Egger test (24). We used STATA, version 9.0 (StataCorp, College Station, Texas), for all analyses. We defined statistical significance as a 2-tailed $p$ value less than 0.05.

Role of the Funding Source

Our study received no outside funding.

### RESULTS

Table 1 summarizes the characteristics of the 14 included studies. We identified 4055 cases of VTE, including 3980 cases in the 11 case–control studies (with 5413 control participants), 29 in the 2 cohort studies (10 932 participants), and 46 in the case–crossover study (5408 participants). Seven of the studies reported statistically significant associations between travel and VTE and 7 reported no significant association, which highlights the heterogeneity of the individual study results.

### Description of Studies

We identified 3 study designs: cohort, case–control, and case–crossover. Two cohort studies evaluated large groups in specific populations, ascertained cases of VTE, and ascertained exposure (travel) status. These cohort designs allowed direct calculation of risk for VTE among those with versus those without exposure and minimized selection and recall bias. Conversely, given the infrequency

| Mode of Travel | Travel History* | Follow-up, wk | Type of VTE | Covariates in the Analysis | Effect Estimate (95% CI)† |
|----------------|-----------------|---------------|-------------|---------------------------|---------------------------|
| Air            | Self-report before diagnosis | 4 | DVT | None | 4.4 (1.0–18.6) |
| Air            | Travel records  | 8 | DVT or PE | Age and sex | 3.2 (1.8–5.6) |
| Air            | Travel records  | 2 | DVT or PE | Within-person analysis adjusted for all non–time-varying covariates | 4.2 (2.9–5.4) |
| Any            | Self-report on admission for VTE | 4 | DVT or PE | Age | 3.9 (1.9–8.4) |
| Any            | Self-report after diagnosis | 3 | DVT | Age and sex | 2.4 (1.4–3.8) |
| Any            | Self-report after diagnosis | 8 | DVT or PE | Age | 2.1 (1.5–3.0) |
| Air            | Report by next of kin after fatal PE | 4 | Fatal PE | Age, sex, electorate, previous VTE, body mass index, immobility >1 wk, recent admission, oral contraceptive and antipsychotic use in preceding 3 mo | 1.8 (0.5–7.1) |
| Air            | Self-report after diagnosis | 4 | DVT or PE | Age, sex, education, body mass index | 2.1 (1.1–4.0) |
| Any            | Self-report before diagnosis | 4 | DVT | Age, sex, symptom duration, previous VTE, cancer, recent surgery, immobilization | 0.7 (0.3–1.4) |
| Any            | Self-report before diagnosis | 4 | DVT | None | 1.4 (0.7–2.6) |
| Any            | Self-report before diagnosis | 2 | DVT | None | 1.3 (0.6–2.8) |
| Any            | Self-report before diagnosis | 4 | DVT | None | 1.7 (0.5–5.7) |
| Any            | Self-report before diagnosis | 4 | PE | None | 1.1 (0.6–1.8) |
| Any            | Self-report after diagnosis | 4 | DVT | Age, sex, family history, previous VTE, factor V Leiden, oral contraceptives, hormone replacement therapy, warfarin use, immobility, trauma | 1.5 (0.9–2.5) |
**Figure 2. Forest plot of the relative risks for travel-related VTE.**

**Study, Year (Reference)**

| Study                                      | Events, n | Relative Risk for VTE (95% CI) | Weight, % |
|--------------------------------------------|-----------|--------------------------------|-----------|
| **All Studies**                            |           |                                |           |
| Ferrari et al, 1999 (11)                   | 160       | 3.9 (1.9–8.4)                  | 6.8       |
| Kraaijenhagen et al, 2000 (4)              | 186       | 0.7 (0.3–1.4)                  | 6.5       |
| Samama, 2000 (12)                          | 494       | 2.4 (1.4–3.8)                  | 8.9       |
| Arya et al, 2002 (6)                       | 185       | 1.4 (0.7–2.6)                  | 7.5       |
| Hosoi et al, 2002 (7)                      | 101       | 1.3 (0.6–2.8)                  | 6.5       |
| ten Wolde et al, 2003 (study 1) (5)        | 58        | 1.7 (0.5–5.7)                  | 3.9       |
| ten Wolde et al, 2003 (study 2) (5)        | 233       | 1.1 (0.6–1.8)                  | 8.3       |
| Kelman et al, 2003 (13)                    | 46        | 4.2 (2.9–5.4)                  | 10.4      |
| Martinelli et al, 2003 (14)               | 210       | 2.1 (1.1–4.0)                  | 7.5       |
| Schwarz et al, 2003 (15)                   | 7         | 4.4 (1.0–18.6)                 | 3.1       |
| Opatrny, 2004 (8)                          | 359       | 1.5 (0.9–2.5)                  | 8.7       |
| Cannegieter et al, 2006 (10)              | 1906      | 2.1 (1.5–3.0)                  | 10.1      |
| Parkin et al, 2006 (9)                     | 88        | 1.8 (0.5–7.1)                  | 3.5       |
| Kuipers et al, 2007 (16)                   | 22        | 3.2 (1.8–5.6)                  | 8.2       |
| **Combined**                               | 4055      | 2.0 (1.5–2.7)                  | 100       |

*P for heterogeneity < 0.001, I² = 70%*

**Studies That Used Nonreferred Patients as Control Participants or a Cohort or Crossover Design**

| Study                                      | Events, n | Relative Risk for VTE (95% CI) | Weight, % |
|--------------------------------------------|-----------|--------------------------------|-----------|
| Ferrari et al, 1999 (11)                   | 160       | 3.9 (1.9–8.4)                  | 9.2       |
| Samama, 2000 (12)                          | 494       | 2.4 (1.4–3.8)                  | 15.8      |
| Kelman et al, 2003 (13)                    | 46        | 4.2 (2.9–5.4)                  | 23.2      |
| Martinelli et al, 2003 (14)               | 210       | 2.1 (1.1–4.0)                  | 11.1      |
| Schwarz et al, 2003 (15)                   | 7         | 4.4 (1.0–18.6)                 | 3         |
| Cannegieter et al, 2006 (10)              | 1906      | 2.1 (1.5–3.0)                  | 21.2      |
| Parkin et al, 2006 (9)                     | 88        | 1.8 (0.5–7.1)                  | 3.5       |
| Kuipers et al, 2007 (16)                   | 22        | 3.2 (1.8–5.6)                  | 13.1      |
| **Combined**                               | 2933      | 2.8 (2.2–3.7)                  | 100       |

*P for heterogeneity = 0.098, I² = 42%*

**Studies That Used Referred Patients as Control Participants**

| Study                                      | Events, n | Relative Risk for VTE (95% CI) | Weight, % |
|--------------------------------------------|-----------|--------------------------------|-----------|
| Kraaijenhagen et al, 2000 (4)              | 186       | 0.7 (0.3–1.4)                  | 9.1       |
| Arya et al, 2002 (6)                       | 185       | 1.4 (0.7–2.6)                  | 18.1      |
| Hosoi et al, 2002 (7)                      | 101       | 1.3 (0.6–2.8)                  | 16.9      |
| ten Wolde et al, 2003 (study 1) (5)        | 58        | 1.7 (0.5–5.7)                  | 22.1      |
| ten Wolde et al, 2003 (study 2) (5)        | 233       | 1.1 (0.6–1.8)                  | 14.3      |
| Opatrny, 2004 (8)                          | 359       | 1.5 (0.9–2.5)                  | 19.5      |
| **Combined**                               | 1122      | 1.2 (0.9–1.6)                  | 100       |

*P for heterogeneity = 0.64, I² = 0%*

VTE = venous thromboembolism.
of travel-related VTE, investigators could identify few total cases among cohorts (29 total cases among 10,932 participants), which limited statistical power.

Eleven retrospective case–control studies identified VTE cases from hospital, clinic, or death records and then selected control participants by various means (nondiseased or non–case patients) who did not have VTE for comparison of likelihood of recent travel (Table 1). Compared with the cohort studies, the case–control design allowed investigators to identify more cases (3980 cases in 11 studies), which increased statistical power. However, unlike cohort studies, case–control studies could not directly calculate risk for VTE among those who traveled versus those who did not. Rather, these studies calculated the odds of travel among those with versus those without VTE to infer risk for VTE among persons who traveled versus those who did not. For these 2 risks to be mathematically equivalent, the likelihood of travel among the selected control participants must be similar to the likelihood of travel in the general population (the study base) from which the case patients came (25, 26).

When selected control participants do not provide an accurate estimate of the average likelihood of travel in the study base, selection bias results. Thus, the ideal control group must be selected by using criteria unrelated to risk for exposure (in this case, travel) among the general population from which the case patients were drawn. Five of the case–control studies we identified used population- or hospital-based control participants with conditions unrelated to travel, such as upper respiratory infection (non–case patients) who did not have VTE for comparison (27–30). In such studies, referred control participants would be more likely to have risk factors for VTE, including likelihood of recent travel, than the true study base.

Finally, 1 study used a case–crossover approach, in which control periods were within-person to eliminate confounding by risk factors for VTE that do not change over time.

The identified studies varied by mode of travel assessed (5 assessed air only and 9 assessed air or surface travel) and minimum duration of travel required for study inclusion (range, >0 to >8 hours). Travel history was ascertained by self-report before diagnosis of VTE in 6 studies, by self-report after diagnosis of VTE in 6 studies, and from pre-existing travel records in 2 studies. One half of the studies evaluated DVT alone, 5 evaluated PE or DVT, and 2 evaluated PE alone. End point ascertainment was fairly uniform: 12 of 14 studies used standard radiologic tests to establish the diagnosis of VTE, 1 used autopsy findings, and 1 used documentation of hospitalization with a primary diagnosis of VTE. Three studies also incorporated D-dimer measurements and clinical probability scores into the VTE diagnostic algorithm (4, 5). Ten studies were in Europe, 2 were in Europe and North America, and 2 were in Australia and New Zealand.

Main Pooled Analysis and Heterogeneity

The pooled relative risk for VTE among travelers across all studies was 2.0 (95% CI, 1.5 to 2.7; P < 0.001).

### Table 2. Association Between Travel and VTE, by Prespecified Study Characteristics and Quality Criteria

| Characteristic | Studies, n | Relative Risk (95% CI) | P Value for Interaction |
|----------------|-----------|------------------------|------------------------|
| **Study design** |           |                        |                        |
| Case–control   | 11        | 1.7 (1.3–2.2)          |                        |
| Cohort         | 2         | 3.3 (2.0–5.7)          |                        |
| Case–crossover | 1         | 4.2 (3.1–5.7)          |                        |
| **Control participant selection in case–control studies** | | | 0.008 |
| Participants referred for VTE evaluation | 6 | 1.2 (0.9–1.6) | |
| Nonreferred control participants | 5 | 2.3 (1.8–2.9) | |
| **Study location** | | | 0.58 |
| Europe | 10 | 1.8 (1.3–2.4) | |
| North America | 2 | 2.2 (1.0–4.5) | |
| Australia and New Zealand | 2 | 3.5 (1.8–6.8) | |
| **Minimum duration of travel** | | | 0.53 |
| <8 h | 2 | 1.9 (1.2–2.7) | |
| ≥8 h | 11 | 2.4 (1.3–4.3) | |
| Not reported | 1 | 2.4 (1.4–3.8) | |
| **Follow-up** | | | 0.31 |
| ≤3 wk | 3 | 2.5 (1.4–4.7) | |
| >3 wk | 11 | 1.8 (1.3–2.5) | |
| **Type of VTE** | | | 0.030 |
| Deep venous thrombosis | 7 | 1.5 (1.1–2.2) | |
| Pulmonary embolism | 2 | 1.1 (0.7–1.9) | |
| Deep venous thrombosis or pulmonary embolism | 5 | 3.0 (2.1–4.2) | |
| **Mode of travel** | | | 0.143 |
| Air | 11 | 2.2 (1.4–3.2) | |
| Surface | 6 | 1.4 (1.0–2.1) | |
| **Source of control population for case–control studies** | | | 0.37 |
| Hospital- or clinic-based | 8 | 1.6 (1.1–2.2) | |
| Population-based | 3 | 2.1 (1.6–2.8) | |
| **Exposure assessment** | | | 0.57 |
| Self-report after VTE diagnosis | 6 | 2.1 (1.7–2.6) | |
| Travel records or self-report before diagnosis | 8 | 1.8 (1.0–3.2) | |
| **Number of covariates controlled for** | | | 0.54 |
| 0 | 5 | 1.3 (0.9–1.8) | |
| 1–3 | 4 | 2.5 (1.9–3.2) | |
| >3 | 5 | 1.8 (0.9–3.6) | |

VTE = venous thromboembolism.

* Studies could contribute to 1 or both estimates depending on modes of travel assessed.
We also found evidence for heterogeneity by type of VTE \((P = 0.030)\), with studies that evaluated DVT and PE demonstrating higher risk \((RR, 3.0)\) than studies that evaluated DVT alone \((RR, 1.5)\). Only 2 studies evaluated PE alone; they indicated no significant association \((RR, 1.1)\) but had wide CIs due to the limited numbers of events in these studies \(\text{(Table 2)}\). We found no evidence for significant differences on the basis of study location, minimum travel duration, follow-up after travel, source of control population, method for exposure assessment, or number of potential confounders controlled for \(\text{(Table 2)}\). The pooled risk estimate for air travel \((RR, 2.2 [CI, 1.4 to 3.2])\) was somewhat higher than for surface travel \((RR, 1.4 [CI, 1.0 to 2.1])\), but this difference was not statistically significant \((P \text{ for heterogeneity} = 0.140)\).

### Dose–Response Relationship

We evaluated evidence for a dose–response relationship among the 8 studies that used nonreferred persons as control participants or used a cohort or case–crossover design. Data on varying risk by duration of travel were available from 4 of these 8 studies \(\text{(9, 10, 14, 16)}\). We identified a significant dose–response relationship \(\text{(Figure 3)}\), with an 18% higher risk for VTE for each 2-hour increase in travel duration \((CI, 4\% \text{ to } 33\%; P = 0.010)\). After we restricted this analysis to the 3 studies with available dose–response data for persons who traveled by air alone, the pooled relative risk demonstrated a 26% higher risk for VTE for each 2-hour increase in travel duration \((CI, 7\% \text{ to } 48\%; P = 0.005)\).

### Publication Bias

We found no significant evidence for publication bias. Our examination of the funnel plot revealed mild asymmetry, with more negative studies published than positive—a pattern opposite to that typically seen with publication bias \(\text{(Figure 4)}\). This asymmetry may have been related to the several negative case–control studies that used a referred

![Figure 3. Relationship between duration of travel and relative risk for venous thromboembolism, as reported by 4 included studies.](image)

![Figure 4. Funnel plot depicting results from the 13 published observational studies.](image)
population for control participants, as previously discussed. The Begg test \( (P = 0.67) \) and the Egger test \( (P = 0.172) \) also provided no statistical evidence for publication bias.

**DISCUSSION**

In this systematic review and meta-analysis of 14 studies that included more than 4000 cases of VTE, we identified a 2-fold higher risk for VTE in travelers than in nontravelers. Of note, significant heterogeneity was present, which was directly related to the method of selection of the comparison group in each study. In case-control studies that used individuals referred for VTE evaluation as control participants, no significant association was found. In contrast, case-control studies that used nonreferred control participants and cohort or case-only studies identified a nearly 3-fold higher risk for VTE in travelers. Our analysis confirms a substantially higher risk for VTE associated with travel and identifies the major source of conflicting results among previous individual studies.

Two previous meta-analyses (27, 28) have investigated whether travel is associated with risk for VTE. The first, which included 4 studies published before 2003, found no definitive evidence that prolonged travel, including air travel, was a risk factor for VTE (pooled odds ratio, 1.70 [CI, 0.89 to 3.22]). In a second meta-analysis, which included 6 case-control studies, the investigators concluded that air travel was not significantly associated with VTE (pooled odds ratio, 1.21 [CI, 0.95 to 1.55]), and a secondary analysis found a small increase in risk when all forms of travel were studied (pooled odds ratio, 1.46 [CI, 1.24 to 1.72]). Neither of these previous meta-analyses (27, 28) reported results in accordance with the MOOSE guidelines or evaluated selection criteria for control participants as a source of heterogeneity, and 1 did not evaluate publication bias (27). Our findings demonstrate for the first time a clear association between travel and VTE (pooled relative risk, 2.8 [CI, 2.2 to 3.7]) and also indicate that failure to consider selection criteria for control participants as a source of heterogeneity results in substantial underestimation of risk.

We identified and quantified a dose-response relationship, observing an 18% higher risk for VTE for each 2-hour increase in travel duration. Because only 4 studies had available data for this assessment, the confidence limits around this estimate are wide (4% to 33% higher risk). Two previous studies (29, 30) evaluated flight distance or duration as a risk factor for PE. These studies included only cases of PE that were brought to medical attention immediately on arrival at the airport (symptomatic PE during a flight) and did not have any information on cases of PE that were diagnosed outside the airport or on cases of DVT diagnosed at any time. Our results, which include studies of both PE and DVT diagnosed up to several weeks after travel, provide the best available estimates of the dose-response relationship between travel duration and VTE. The demonstration of a dose-response relationship suggests a causal nature to the observed relationship between travel and VTE, particularly as related to the potential role of stasis. These findings also highlight a relevant and identifiable characteristic of travel that can predict greatest risk: longer duration of travel. Among studies that evaluated air travel alone, the dose-response relationship seemed stronger (26% higher risk per 2 hours of travel), but we had insufficient data to compare directly pooled dose-response estimates for air versus surface travel.

Several factors provide plausible biological mechanisms for an effect of travel on risk for VTE. Stasis and hypercoagulability, 2 components of the Virchow triad, are known to occur during travel and would increase the risk for VTE. Several pathophysiologic studies (31–35) have investigated the possible induction of a hypercoagulable state during travel and assessed changes in blood levels of proteins involved in thrombin generation or fibrinolysis. These studies have generally been performed in a small number of healthy volunteers who were traveling or immobilized for study purposes, and the results of these studies have been inconsistent. Further research is required to understand the effects of travel on stasis, thrombogenesis, and other risk factors for VTE and to help guide potential preventive therapies to mitigate these pathways. Such studies should test more participants during actual travel and compare the results with those of similar tests conducted during stable periods of nontravel or with results from other, nontraveling individuals.

Whereas our analysis identifies a 3-fold higher relative risk for VTE with travel, the absolute risk is also relevant to guide both policy and individual decisions about prevention. One retrospective cohort study (16) estimated the absolute risk for VTE to be 1 case in 4600 airline flights. The study drew its sample from healthy employees of multinational organizations and only included first episodes of VTE that did not result in death or loss of employment. Thus, the observed absolute risk may not be generalizable to all travelers, particularly travelers who may be at higher risk for VTE, such as older persons, pregnant women, or persons with a history of VTE. Nonetheless, the findings of this report suggest that, at least among generally healthy individuals, even a 3-fold increase in relative risk is unlikely to produce a sufficiently high absolute risk to justify higher-risk interventions, such as oral anticoagulation during travel. However, VTE is often clinically serious or fatal, and the nearly 3-fold higher relative risk our analysis demonstrates the need for better investigation of general preventive measures that could be effective, such as increased hydration or ambulation. Indirect evidence from pathophysiologic studies (31, 36) suggests that dehydration and immobilization can alter serum levels of markers of thrombin generation or fibrinolysis in healthy volunteers, and investigation of whether related countermeasures can reduce risk for travel-related VTE is warranted.
Several randomized clinical trials (37–42) have evaluated the efficacy of lower-extremity elastic compression stockings for prevention of travel-related DVT. These trials have generally reported compression stockings to be effective, at least for preventing DVT in the calf, although nearly all of these trials were performed by 1 research group (37–41), whose methods for reporting of results have been questioned (43).

Our dose–response analysis indicates that general preventive measures for VTE may be particularly important as travel duration increases. In addition, researchers should consider evaluating additional preventive measures for persons who may be at higher absolute risk for VTE, such as those who have thrombophilia (14), are receiving oral contraceptives (9), or are obese (15), particularly for longer trips.

Our demonstration of heterogeneity by study design highlights the importance of basic principles in the design and evaluation of otherwise well-conceived epidemiologic studies. Studies that selected control participants on the basis of referral for VTE evaluation—because “controls should consist of people with similar signs and symptoms as cases” (4)—found no significant relationship between travel and VTE (4–7). A common misperception is that control participants in a case–control study should be as similar as possible to the case patients except for the exposure of interest. Part of this misperception may result from the concept of matching; during selection of control participants, matching on certain characteristics can increase efficiency (statistical power) during adjustment by minimizing stratified $2 \times 2$ tables that lack cases or noncases in the classical Mantel–Haenszel approach (44). Investigators commonly use important risk factors for the outcome for matching; for example, age is a common matching factor in many studies. However, matching should be used cautiously to prevent selection bias—matching on factors related to the likelihood of exposure (in this case, travel)—in the study base. This misperception may also stem from the use of the term control participants to describe 2 very different groups: unexposed persons in randomized trials and nondiseased persons in case–control studies. In trials, randomization to an intervention allows for untreated or unexposed persons (control participants) to be as similar as possible to treated or exposed persons in all other respects. Conversely, in a case–control study, control participants are nondiseased persons (non–case patients), not untreated or unexposed persons. In any study design—case–control, cohort, or randomized trial—persons who do not experience a disease should never be expected to be similar to the case patients; those who develop a disease will always have many more risk factors for disease than those who do not develop the disease.

In these studies, cases occurred in a particular general population (the study base). In cohort studies, this study base was explicitly identifiable as the total cohort who developed VTE. In case–control studies, the study base was conceptually identical—the general population of persons who might travel and, if they experienced VTE, be identified as a case patient in that study—but not explicitly identifiable; unlike cohort studies, no roster of persons was available to identify the study base precisely. Thus, appropriate selection of control participants was critical for these studies to accurately estimate the average exposure status in the study base. Many different selection strategies can be valid, including random-digit telephone calls or use of hospital-based control participants, as long as the methods are unrelated to the likelihood of exposure (in this case, travel) in the general population in which the cases occurred. When any of the selection criteria for control participants are related to likelihood of travel, selection bias results because the likelihood of travel in the study base is incorrectly estimated. Our findings highlight the important consequences of such selection bias. In the case of travel and risk for VTE, individuals referred for VTE evaluation would have, on average, more risk factors for VTE, including likelihood of travel, than the general population. Thus, the use of such control participants will lead to underestimation (bias toward null) of the true associations between travel and VTE because of underestimation of the true contrast between the likelihood of travel in the case-patients and the study base. Failure to recognize this selection bias would lead to erroneous conclusions regarding the presence and magnitude of travel effects on risk for VTE. Some of these referred control participants may also have had false-negative test results (they may have had VTE). Inclusion of these persons as control participants would lead to further underestimation of the true association of travel with VTE (bias toward the null due to misclassification of VTE). In contrast to the clear heterogeneity from selection criteria for control participants, the absence of heterogeneity from method or timing of exposure assessment argued against the presence of substantial recall bias in the identified studies (Table 2).

Our study has limitations. We may not have accounted for all sources of heterogeneity among the studies; however, after we stratified by selection criteria for control participants, our results were concordant within each of the 2 strata and neither clinical nor statistical heterogeneity was apparent. Recall bias may have affected the individual study results; however, absence of heterogeneity by method or timing of exposure assessment argues against substantial effects of recall bias. A remote possibility exists that some control participants had unrecognized VTE, a misclassification error that would result in bias toward the null. As in any meta-analysis that uses grouped data from separate published studies, we cannot be certain that our estimates are free of all confounding from individual level variables; however, we detected no heterogeneity on the basis of the number of covariates included for multivariable adjustment. The results of our meta-analysis should apply to general populations in Western countries because each of the identified studies was performed in Western popula-
tions. Although generalizability to non-Western populations should be confirmed, the biological mechanisms that predispose to travel-related VTE should be similar in most racial and ethnic groups, with the exception of such genetic risk factors as factor V Leiden. Finally, publication bias is a potential limitation of any meta-analysis, although the funnel plot and statistical evaluation in our study did not suggest any appreciable publication bias.

In conclusion, travel is associated with a 3-fold higher risk for VTE, with a dose–response relationship of 18% higher risk for each 2-hour increase in travel duration. These findings provide the strongest evidence to date of the presence and magnitude of the association between travel and VTE. They also indicate that the efficacy of low-cost and low-risk interventions, such as increased hydration and ambulation, should be investigated for all general travelers—particularly those with longer durations of travel—and that additional interventions and therapies should be evaluated for higher-risk subgroups.

From Harvard School of Public Health, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Divay Chandra, MD, MSc, Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115; e-mail, dchandra@hsph.harvard.edu.

Current author addresses are available at www.annals.org.

References

1. World Health Organization. Research Into Global Hazards of Travel (WRIGHT) Project: Final Report of Phase I. Geneva: World Health Organization; 2007. Accessed at www.who.int/cardiovascular_diseases/wright_project/phase1_report/en/index.html on 12 June 2009.
2. ter Kuile A. A New Approach to Sovereignty. International Civil Aviation Organization Journal. 2008;63:36. Accessed at www.icao.int/icao/en/fp/2008/6301_en.pdf on 12 June 2009.
3. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117:19-25. [PMID: 15210384]
4. Kraaijehagen RA, Haverkamp D, Koopman MM, Prandoni P, Piovella F, Büller HR. Travel and risk of venous thrombosis [Letter]. Lancet. 2000;356:1492-3. [PMID: 11081538]
5. ten Wolde M, Kraaijehagen RA, Schierke J, Hagen PJ, Mathijssen JJ, Mac Gillavry MR, et al. Travel and the risk of symptomatic venous thromboembolism. Thromb Haemost. 2003;89:499-505. [PMID: 12624634]
6. Aya R, Barnes JA, Hossain U, Patel RK, Cohen AT. Long-haul flights and deep vein thrombosis: a significant risk only when additional factors are also present. Br J Haematol. 2002;116:653-4. [PMID: 11849227]
7. Hossi Y, Geroulakos G, Belcaro G, Sutton S. Characteristics of deep vein thrombosis associated with prolonged travel. Eur J Vasc Endovasc Surg. 2002;24:235-8. [PMID: 12122785]
8. Opatrny L. A Case–Control Study Examining the Association Between Travel and Deep Venous Thrombosis [Master’s Thesis]. Montreal, Quebec, Canada: McGill Univ; 2004.
9. Parkin L, Bell ML, Herbison GP, Paul C, Skegg DC. Air travel and fatal pulmonary embolism. Thromb Haemost. 2006;95:807-14. [PMID: 16676072]
10. Cannegieter SC, Doggen CJ, van Houwelingen HC, Rosendaal FR. Travel-related venous thrombosis: results from a large population-based case control study (MEGA study). PLoS Med. 2006;3:e307. [PMID: 16933962]
11. Ferrari E, Chevalier T, Chapelier A, Baudouy M. Travel as a risk factor for venous thromboembolic disease: a case-control study. Chest. 1999;115:440-4. [PMID: 10027445]
12. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000;160:3415-20. [PMID: 11112234]
13. Kelman CW, Kortt MA, Becker NG, Li Z, Mathews JD, Guest CS, et al. Deep vein thrombosis and air travel: record linkage study. BMJ. 2003;327:1072. [PMID: 14604926]
14. Martellini I, Taitoli E, Battaglioli T, Poddà GM, Passamonti SM, Pedotti P, et al. Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives. Arch Intern Med. 2003;163:2771-4. [PMID: 14662632]
15. Schwarz T, Siegert G, Oeteter W, Halbritter K, Beyer J, Frommhold R, et al. Venous thrombosis after long-haul flights. Arch Intern Med. 2003;163:2759-64. [PMID: 14662630]
16. Kuipers S, Cannegieter SC, Middeldorp S, Robyn L, Büller HR, Rosendaal FR. The absolute risk of venous thrombosis after air travel: a cohort study of 8,859 employees of international organisations. PLoS Med. 2007;4:e290. [PMID: 17898662]
17. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-Analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-12. [PMID: 10789670]
18. Dimberg LA, Mundt KA, Sulsky SL, Liese BH. Deep vein thrombosis associated with corporate air travel. J Travel Med. 2001;8:127-32. [PMID: 11468114]
19. Jacobson BF, Münster M, Smith A, Burnand KG, Carter A, Abdool-Carrim AT, et al. The BEST study—a prospective study to compare business class versus economy class air travel as a cause of thrombosis. S Afr Med J. 2003;93:522-8. [PMID: 12939926]
20. Joseph CL, Ownby DR, Peterson EL, Johnson CC. Racial differences in physiologic parameters related to asthma among middle-class children. Chest. 2000;117:1356-44. [PMID: 10807820]
21. Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999;282:1054-60. [PMID: 10493204]
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. [PMID: 3802833]
23. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-101. [PMID: 7786990]
24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34. [PMID: 9310563]
25. Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in case-control studies. I. Principles. Am J Epidemiol. 1992;135:1019-21.[PMID: 1612070]
26. Rothman KJ. Types of epidemiologic study. In: Rothman KJ, eds. Epidemiology: An Introduction. 1st ed. New York: Oxford Univ Pr; 2002:73.
27. Adi Y, Bayliss S, Rouse A, Taylor RS. The association between air travel and deep vein thrombosis: systematic review & meta-analysis. BMC Cardiovasc Disord. 2004;4:7. [PMID: 15151705]
28. Trujillo-Santos AJ, Jiménez-Puente A, Perea-Milla E. Association between long travel and venous thromboembolic disease: a systematic review and meta-analysis of case-control studies. Ann Hematol. 2008;87:79-86. [PMID: 17899081]
29. Lapostolle F, Surget V, Borron SW, Desmaizieres M, Sordelet D, Lapandry C, et al. Severe pulmonary embolism associated with air travel. N Engl J Med. 2001;345:779-83. [PMID: 11565296]
30. Pérez-Rodríguez E, Jiménez Díaz G, Pérez-Walton I, Luque M, Guillén C, et al. Incidence of air travel-related pulmonary embolism at the Madrid-Barajas airport. Arch Intern Med. 2003;163:2766-70. [PMID: 14662631]
31. Bendz B, Rostrup M, Severe K, Andersen TO, Sandset PM. Association between acute hypobaric hypoxia and activation of coagulation in human beings [Letter]. Lancet. 2000;356:1657-8. [PMID: 11089830]
32. Crosby A, Talbot NP, Harrison P, Keeling D, Robbins PA. Relation between acute hypoxia and activation of coagulation in human beings. Lancet. 2003;361:2207-8. [PMID: 12842377]
33. Stricker H, Colucci G, Alberti L, Bombelli G. Variation in coagulation inhibitors during prolonged sitting: possible pathogenetic mechanisms for travel-associated thrombosis [Letter]. J Thromb Haemost. 2006;4:900-2. [PMID: 16844944]
Review

Travel and Risk for Venous Thromboembolism

34. Tardy B, Tardy-Poncet B, Bara L, Laporte-Simitisidis S, Rascle F, Samama MM, et al. Effects of long travels in sitting position in elderly volunteers on biological markers of coagulation activation and fibrinolysis. Thromb Res. 1996; 83:153-60. [PMID: 8837314]

35. Toff WD, Jones CI, Ford I, Pearse RJ, Watson HG, Watt SJ, et al. Effect of hypobaric hypoxia, simulating conditions during long-haul air travel, on coagulation, fibrinolysis, platelet function, and endothelial activation. JAMA. 2006; 295:2251-61. [PMID: 16705106]

36. Schobersberger W, Mittermayr M, Innerhofer P, Sumann G, Schobersberger B, Klingler A, et al. Coagulation changes and edema formation during long-distance bus travel. Blood Coagul Fibrinolysis. 2004;15:419-25. [PMID: 15205591]

37. Belcaro G, Cesaroni MR, Nicolaides AN, Ricci A, Geroulakos G, Shah SS, et al. Prevention of venous thrombosis with elastic stockings during long-haul flights: the LONFLIT 5 JAP study. Clin Appl Thromb Hemost. 2003;9:197-201. [PMID: 14507107]

38. Belcaro G, Cesaroni MR, Shah SS, Nicolaides AN, Geroulakos G, Ippolito E, et al. Prevention of edema, flight microangiopathy and venous thrombosis in long flights with elastic stockings. A randomized trial: The LONFLIT 4 Concorde Edema-SSL Study. Angiology. 2002;53:63-5. [PMID: 12463616]

39. Belcaro G, Geroulakos G, Nicolaides AN, Myers KA, Winford M. Venous thromboembolism from air travel: the LONFLIT study [Editorial]. Angiology. 2001;52:369-74. [PMID: 11437026]

40. Cesaroni MR, Belcaro G, Errichi BM, Nicolaides AN, Geroulakos G, Ippolito E, et al. The LONFLIT4—Concorde Deep Venous Thrombosis and Edema Study: prevention with travel stockings. Angiology. 2003;54:143-54. [PMID: 12678188]

41. Cesaroni MR, Belcaro G, Nicolaides AN, Geroulakos G, Lennox A, Myers KA, et al. The LONFLIT4-Concorde—Sigvaris Traveno Stockings in Long Flights (EcoTraS) Study: a randomized trial. Angiology. 2003;54:1-9. [PMID: 12593490]

42. Scrr JH, Machin SJ, Bailey-King S, Mackie IJ, McDonald S, Smith PD. Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomized trial. Lancet. 2001;357:1485-9. [PMID: 11377600]

43. Kuipers S, Schreijer AJ, Cannegieter SC, Büller HR, Rosendaal FR, Middeldorp S. Travel and venous thrombosis: a systematic review. J Intern Med. 2007;262:615-34. [PMID: 18028182]

44. Stürmer T, Brenner H. Potential gain in precision and power by matching on strong risk factors in case-control studies: the example of laryngeal cancer. J Epidemiol Biostat. 2000;5:125-31. [PMID: 10890284]

For more information
Annette Flanagin
jama-peer@jama-archives.org

Details available at www.jama-peer.org
Current Author Addresses: Drs. Chandra and Parisini: Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115.

Dr. Mozaffarian: Department of Epidemiology, Harvard School of Public Health, 665 Huntington Avenue, Building 2-319, Boston, MA 02115.